SCHEMBL14769222

SCHEMBL14769222

CC(C)(C)OC(=O)Nc1cccc(Cc2nc(S(C)(=O)=O)ncc2C(=O)Nc2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
NPC1 O15118 3/20 0.42
TLR9 Q9NR96 3/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TP53 P04637 1/20 0.41
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
KAT6A Q92794 1/20 0.40
NAMPT P43490 1/20 0.40
TOP2A P11388 1/20 0.40
TOP2B Q02880 1/20 0.40
HSP90AA1 P07900 1/20 0.40
PTPN11 Q06124 1/20 0.40
MITF O75030 1/20 0.39
S1PR4 O95977 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14769164 0.87 AURKA (0.41) MAPTSIRT2NPC1TLR9KMT2A
SCHEMBL14769152 0.86 KMT2A (0.47) MAPTSIRT2KMT2AMEN1LMNA
SCHEMBL14772001 0.85 BTK (0.44) MAPTSIRT2NPC1TLR9KMT2A
SCHEMBL13498138 0.83 BTK (0.50) MAPTNPC1TLR9KMT2ARAB9A
SCHEMBL2362339 0.81 NPC1 (0.48) MAPTNPC1TLR9KMT2ARAB9A
SCHEMBL14769135 0.80 CNR2 (0.53) MAPTKMT2AMEN1LMNATP53
SCHEMBL14769183 0.78 SIRT2 (0.46) MAPTSIRT2KMT2AMEN1LMNA
SCHEMBL14769185 0.74 RXFP1 (0.51) MAPTSIRT2KMT2AMEN1LMNA
SCHEMBL14769153 0.73 HTT (0.51) MAPTSIRT2KMT2AMEN1LMNA
SCHEMBL14772002 0.72 POLB (0.53) MAPTSIRT2LMNARXFP1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710222-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2014-04-29 US disclosed
US-8710222-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2014-04-29 US disclosed
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2013-03-14 US disclosed
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 MAPT 1888/4885SIRT2 1770/4885NPC1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.